Showing 2121-2130 of 2735 results for "".
- Sofwave Ultrasound Technology Remodels Collagen, Elastin, and Hyaluronic Acid in the Skinhttps://modernaesthetics.com/news/sofwave-ultrasound-technology-remodels-collagen-elastin-and-hyaluronic-acid-in-the-skin/2483484/Sofwave’s ultrasound technology is a noninvasive treatment designed to lift sagging skin on the face and neck, improve laxity on the upper arms, and reduce fine lines and wrinkles. It can also address acne scars and the short-term appearance of cellulite. The company hosted an event in New York C
- Epicutis Launches Lipid Shield SPF 30https://modernaesthetics.com/news/epicutis-launches-lipid-shield-spf-30/2483432/Epicutis has launched a mineral-based sunscreen, Lipid Shield SPF 30. In a press release, the company stated the Lipid Shield SPF 30 is the only sunscreen to pair non-nano zinc oxide with a proprietary molecule known as disodium tetramethylhexadecenyl succinoyl cysteine (TSC). TSC, a lipid
- Sciton Launches Multi-Wavelength Resurfacing Laser Platformhttps://modernaesthetics.com/news/sciton-launches-multi-wavelength-resurfacing-laser-platform/2483427/Sciton, Inc. has introduced HALO® TRIBRID™, a laser platform that integrates 3 wavelengths—2940 nm, 1927 nm, and 1470 nm—into a single resurfacing device. The system combines the company’s previously distinct technologies (HALO®, MOXI™, and Erbium Resurfacing) into one handpiece, allowing provide
- Hugel Marks 15 Years of Letybo with 2025 H.E.L.F Symposium in Seoulhttps://modernaesthetics.com/news/hugel-marks-15-years-of-letybo-with-2025-helf-symposium-in-seoul/2483385/More than 220 medical professionals from across the globe gathered in Seoul on September 14 for Hugel Inc.’s 2025 H.E.L.F. symposium, marking 15 years since the launch of its botulinum toxin, Letybo. The Hugel Expert Leader’s Forum was held at Seoul Dragon City under the theme, “K-Beau
- New HA Filler Obagi® saypha® MagIQ™ Approved by FDAhttps://modernaesthetics.com/news/new-ha-filler-obagi-saypha-magiq-approved-by-fda/2483329/The US Food and Drug Administration (FDA) has approved Obagi® saypha® MagIQ™, an injectable hyaluronic acid (HA) gel, marking the first product in the Obagi® saypha® collection under the Obagi Medical brand, Waldencast plc announced.
- Study Links Personality Traits to Rhinoplasty Satisfactionhttps://modernaesthetics.com/news/study-links-personality-traits-to-rhinoplasty-satisfaction/2483320/A new study published in Aesthetic Plastic Surgery suggests a distinct relationship between personality traits and satisfaction with rhinoplasty outcomes. The study, titled “Rhinoplasty and the ‘Big Five’ Model: The Impact of Patients’ Personality Traits on Post-surgical Satisfac
- iS Clinical Launches Hydrating Antioxidant Moisturizer Targeting Aging, Environmental Stresshttps://modernaesthetics.com/news/is-clinical-launches-hydrating-antioxidant-moisturizer-targeting-aging-environmental-stress/2483299/iS Clinical has introduced a new hydration-focused formulation, Daily Dynamic Hydrator, which is the company’s most advanced moisturizing product to date, according to a press release. The formulation is positioned as a 3-in-1 moisturizer that supports skin hydration, antioxidant protecti
- Study Identifies Age-Related Collagen Changes in Vaginal Tissuehttps://modernaesthetics.com/news/study-identifies-age-related-collagen-changes-in-vaginal-tissue/2483214/A new study published in the Aesthetic Surgery Journal has identified key age-related changes in vaginal wall collagen that may contribute to the progressive degeneration of the female reproductive system. The study, titled “Age-Associated Collagen Remodeling in Vaginal Tissue: A
- Revance Brings Mepivacaine-Based Fillers to US Markethttps://modernaesthetics.com/news/revance-brings-mepivacaine-based-fillers-to-us-market/2483155/Revance has announced the US launch of the Teoxane RHA® Collection with Mepivacaine, marking a significant innovation in dermal filler formulations. The update reflects a shift in anesthetic agents used in hyaluronic acid fillers, with mepivacaine replacing lidocaine as the primary ane
- Oral GLP-1 Hits Phase 3 Trial Targets; Regulatory Submissions Cominghttps://modernaesthetics.com/news/oral-glp-1-hits-phase-3-trial-targets-regulatory-submissions-coming/2483149/Eli Lilly and Company announced positive topline results from its Phase 3 ATTAIN-2 trial, showing that its investigational oral GLP-1 receptor agonist, orforglipron, achieved significant weight loss and improved cardiometabolic outcomes in adults with obesity or overweight status and type 2 diabe